A hallmark of TDT's fundamental operating philosophy is the creation of strategic technology and business alliances. The objective of these alliances is to create the optimum path to transform basic research technology into practically applied diagnostic and therapeutic products, as rapidly and safely as possible. Several discussions are underway, in addition to those listed below.


Thomas Jefferson University

In 1994, TDT successfully negotiated a Research Funding Agreement with Thomas Jefferson University. Under this agreement, TDT has agreed to provide funding for sponsored research in colorectal cancer receptors and certain other technologies in the field of cancer and certain infectious diseases. Much of this work is being conducted in the laboratories of Scott A. Waldman, M.D., Ph.D., Samuel V. Hamilton Professor of Medicine, Division of Clinical Pharmacology at Thomas Jefferson University.

Millennium Pharmaceuticals, Inc.

In November 2001, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced that TDT has granted Millennium a license to TDT's intellectual property surrounding guanylyl cyclase C (GC-C), a protein uniquely expressed on the cell surface of colorectal tumors, and its related ST ligand for use in colorectal cancer therapeutics. Millennium intends to utilize these advanced components to develop both toxin and antibody-based therapeutics directed against colorectal cancer. Due to the utility demonstrated in preclinical work, Millennium believes there is potential to create highly specific therapies that may offer significantly improved efficacy and safety in the fight against metastatic colorectal cancer.

Millennium Pharmaceutical's Website